866-997-4948(US-Canada Toll Free)

Smallpox-Pipeline Review, H2 2019

Published By :

Global Markets Direct

Published Date : Aug 2019

Category :

Pharmaceutical

No. of Pages : 77 Pages

Smallpox - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Smallpox - Pipeline Review, H2 2019, provides an overview of the Smallpox (Infectious Disease) pipeline landscape.

Smallpox is an acute contagious infection caused by the Variola virus. Symptoms include fever, malaise, headache, prostration, severe back pain, abdominal pain and vomiting. This is followed by the development of rashes on the face, hands, forearms and the trunk. Lesions develop in the mucous membranes of the nose and mouth which ulcerate, releasing large amounts of virus into the mouth and throat. Treatment includes medications such as antiviral and lifestyle modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Smallpox - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Smallpox (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Smallpox (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 1, 1, 6 and 3 respectively.

Smallpox (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Smallpox (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Smallpox (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Smallpox (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Smallpox (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Smallpox (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Smallpox (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Smallpox (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Smallpox - Overview
Smallpox - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Smallpox - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Smallpox - Companies Involved in Therapeutics Development
Bavarian Nordic A/S
BioFactura Inc
CEL-SCI Corp
Chimerix Inc
CJ HealthCare Corp
EpiVax Inc
SIGA Technologies Inc
Tonix Pharmaceuticals Holding Corp
Smallpox - Drug Profiles
brincidofovir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-40011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Smallpox and Vaccinia Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Smallpox - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
smallpox [ankara] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
smallpox vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tecovirimat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNX-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIR-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Smallpox - Dormant Projects
Smallpox - Discontinued Products
Smallpox - Product Development Milestones
Featured News & Press Releases
Jul 08, 2019: SIGA awarded Department of Defense contract to develop expanded indication for TPOXX as post-exposure prophylactic for smallpox
Jun 19, 2019: Bavarian Nordic initiates phase 3 trial of freeze-dried MVA-BN smallpox vaccine
May 20, 2019: SIGA announces exercise of option for the purchase of raw materials for oral TPOXX manufacturing totaling $11 million
Mar 11, 2019: Bavarian Nordic announces FDA delay in the review of the Biologics License Application for MVA-BN Smallpox Vaccine
Jan 18, 2019: Bavarian Nordic announces exercise of USD 44 million option by the U.S. Government under contract for freeze-dried MVA-BN Smallpox vaccine
Dec 21, 2018: Bavarian Nordic announces FDA acceptance and Priority Review of Biologics License Application for MVA-BN Smallpox Vaccine
Nov 01, 2018: SIGA announces Priority Review Voucher transaction totaling $80 million
Oct 05, 2018: Chimerix presents results from multiple ascending dose study of IV Brincidofovir at IDWeek
Oct 04, 2018: Landmark adVance study shows adenovirus burden correlates with mortality in pediatric allogeneic hematopoietic cell transplant recipients
Sep 19, 2018: Bavarian Nordic delivers Smallpox Vaccine to England in response to current Monkeypox Cases
Sep 10, 2018: SIGA Technologies awarded BARDA contract for TPOXX
Aug 21, 2018: Importance of Smallpox vaccination highlighted in biopreparedness exercise
Aug 09, 2018: Bavarian Nordic Granted EUR 30 Million loan from The European Investment Bank
Jul 13, 2018: FDA approves TPOXX as first drug to treat smallpox
Jul 05, 2018: Pivotal Trial Data for SIGA Technologies Oral TPOXX Published in the New England Journal of Medicine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Smallpox, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Smallpox - Pipeline by Bavarian Nordic A/S, H2 2019
Smallpox - Pipeline by BioFactura Inc, H2 2019
Smallpox - Pipeline by CEL-SCI Corp, H2 2019
Smallpox - Pipeline by Chimerix Inc, H2 2019
Smallpox - Pipeline by CJ HealthCare Corp, H2 2019
Smallpox - Pipeline by EpiVax Inc, H2 2019
Smallpox - Pipeline by SIGA Technologies Inc, H2 2019
Smallpox - Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2019
Smallpox - Dormant Projects, H2 2019
Smallpox - Dormant Projects, H2 2019 (Contd..1), H2 2019
Smallpox - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Smallpox, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *